Shingles Market to Grow Significantly by 2032 | Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immorna Biotherapeutics Inc., and others.

{Delhi, India} To strategically aid Shingles Companies in developing drugs for Shingles, DelveInsight launched a report titled “Shingles Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology-based market analysis, providing a roadmap for success in the dynamic landscape of the Shingles Market.

Download a free sample copy of the “Shingles Market Report”

Key Highlights from the Shingles Market Research Report

• The Shingles Market Size in the 7MM was found to be around USD 8,500 million, in 2022. It will increase during the forecast period (2023–2032), owing to the launch of upcoming therapies and prophylactic measures.
• As per DelveInsight’s estimates, among the 7MM, the lowest number of healthy patient population at risk for herpes zoster was found to be in Spain. In 2022, the number of healthy patient populations at risk for herpes zoster in Spain was found to be approximately 18 million.
• The launch of novel therapies would significantly contribute towards an increase in Shingles market size in the 7MM.
• The leading companies working in the Shingles Market include Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immorna Biotherapeutics Inc., ICON plc, Pascoe Pharmazeutische Praeparate GmbH, Merck Sharp & Dohme LLC, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Jiangsu Rec-Biotechnology Co., Ltd., Astellas Pharma Inc., and others.
• Promising Shingles Pipeline Therapies in the various stages of development include CRV-101, JCXH-105, Valacyclovir, FV-100, PED-HZ/su, REC610, Foscarnet Sodium, Acyclovir, RZV, and others.

Shingles Country-based Treatment Analysis

The Shingles treatment market report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in Shingle's therapies that have potential treatment paradigms and improve patient outcomes.

Shingles, also known as herpes zoster, is a viral infection caused by the varicella-zoster virus—the same virus responsible for chickenpox. After a person recovers from chickenpox, the virus remains dormant in nerve cells and can be reactivated later in life, leading to the development of shingles.

Download the report to understand which factors are driving Shingles Epidemiology trends @ Shingles Epidemiology Forecast

Shingles Epidemiology Insights

The report proffers historical and forecasted epidemiology insights that help to understand the target patient population for Shingles. The analysis is from 2019-2032, providing insights into how the patient trends are going to shape Shingle's market dynamics. Further, the epidemiology is segmented to provide an in-depth analysis of patient pools allowing companies to understand their target patient pools.

Shingles Epidemiology Segmentation in the 7MM

• Total Healthy Patient Population at-risk for Herpes Zoster
• Eligible Patient Population for Herpes Zoster Vaccination

“In the DelveInsight model, for the epidemiology assessment of Herpes Zoster in the 7MM, evaluations were done based on focusing on epidemiological assumptions pertaining to preventive treatments only, hence inclusion the healthy patients at risk and eligible patients for treatment”

Shingles Companies and Drugs

• Curevo Inc.: CRV-101
• Immorna Biotherapeutics Inc.: JCXH-105
• Merck Sharp & Dohme LLC: Zoster vaccine live (Oka/Merck)
• Bristol-Myers Squibb: Valacyclovir
• GlaxoSmithKline: PED-HZ/su
• Jiangsu Rec-Biotechnology Co., Ltd: REC610

To learn more about Shingles Companies working in the treatment market, visit @ Shingles Clinical Trials and Therapeutic Assessment

Shingles Treatment Market

Treatment for Shingles must be initiated by a dermatologist or other health-care provider within three days of getting the rash. Ideally, if the treatment is initiated within three days, it can prevent possible complications, such as long-lasting nerve pain. Antiviral medication and vaccinations are often the most effective shingles treatments, according to the National Foundation for Infectious Diseases.

Shingles Market Insights

Approximately one in three people in the United States will develop shingles at some point in their life. Though prompt treatment with oral antiviral agents such as acyclovir, valacyclovir, and famciclovir decreases the severity and duration of acute pain, prevention from VZV is needed to decrease the socioeconomic burden of this disease. As per our analysis, the overall market size of shingles is expected to increase due to the expected launch of therapies during the forecast period.

Shingles Emerging Drugs

• FOSTOIN
• CRV 101
• EG-HZ

Discover more about therapies set to grab major Shingles Market Share @ Shingles Treatment Market

Scope of the Shingles Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Shingles Companies- Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immorna Biotherapeutics Inc., ICON plc, Pascoe Pharmazeutische Praeparate GmbH, Merck Sharp & Dohme LLC, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Jiangsu Rec-Biotechnology Co., Ltd., Astellas Pharma Inc., and others.
• Shingles Pipeline Therapies- CRV-101, JCXH-105, Valacyclovir, FV-100, PED-HZ/su, REC610, Foscarnet Sodium, Acyclovir, RZV, and others.

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Shingles Market Landscape.

Gain Competitive Edge in the Indication Market: Understand the current landscape of the Shingles Market, including the competitive environment, key companies developing drugs for Shingles, and their strategies. By analyzing Shingles Market Dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the Shingles Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Shingles. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the Shingles market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Shingles Market with clarity and purpose.

Read our Blogs- Pharmaceutical and Biotech Insight, News and Blog Posts

Related Reports

Shingles Epidemiology Forecast 2032

DelveInsight's Shingles Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.

Shingles Pipeline Insight 2023

Shingles Pipeline Insights, 2023 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across.

Explore Our Success Story of Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study! 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/